BioSyent Inc.
RX.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 30.16M | 28.30M | 27.48M | 25.56M | 25.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.16M | 28.30M | 27.48M | 25.56M | 25.36M |
| Cost of Revenue | 6.80M | 6.17M | 5.90M | 5.24M | 5.22M |
| Gross Profit | 23.37M | 22.13M | 21.58M | 20.32M | 20.14M |
| SG&A Expenses | 18.89M | 18.14M | 18.02M | 17.30M | 14.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.86M | 25.48M | 25.09M | 23.72M | 19.28M |
| Operating Income | 9.59M | 9.10M | 8.67M | 8.13M | 6.08M |
| Income Before Tax | 8.44M | 7.97M | 7.56M | 7.15M | 6.90M |
| Income Tax Expenses | 2.27M | 2.05M | 1.94M | 1.83M | 1.68M |
| Earnings from Continuing Operations | 6.18 | 5.92 | 5.62 | 5.31 | 5.23 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.18M | 5.92M | 5.62M | 5.31M | 5.23M |
| EBIT | 9.59M | 9.10M | 8.67M | 8.13M | 6.08M |
| EBITDA | 10.34M | 9.78M | 9.35M | 8.78M | 6.40M |
| EPS Basic | 0.55 | 0.52 | 0.49 | 0.46 | 0.45 |
| Normalized Basic EPS | 0.57 | 0.54 | 0.52 | 0.49 | 0.37 |
| EPS Diluted | 0.54 | 0.51 | 0.48 | 0.45 | 0.44 |
| Normalized Diluted EPS | 0.56 | 0.53 | 0.51 | 0.48 | 0.36 |
| Average Basic Shares Outstanding | 45.28M | 45.61M | 45.95M | 46.34M | 46.65M |
| Average Diluted Shares Outstanding | 46.23M | 46.55M | 46.84M | 47.20M | 47.50M |
| Dividend Per Share | 0.14 | 0.14 | 0.13 | 0.13 | 0.13 |
| Payout Ratio | 25.50% | 26.15% | 27.10% | 28.59% | 28.69% |